Collegium Pharmaceutical, which is developing an abuse-deterrent oral formulation of oxycodone for pain, announced terms for its IPO on Monday.
The Canton, MA-based company plans to raise $75 million by offering 5.8 million shares at a price range of $12 to $14. At the midpoint of the proposed range, Collegium Pharmaceutical would command a market value of $256 million.
Collegium Pharmaceutical, which was founded in 2002, plans to list on the NASDAQ under the symbol COLL. Jefferies and Piper Jaffray are the joint bookrunners on the deal. It is expected to price during the week of May 4, 2015.
